Filing Analysis
HeartBeam, Inc. entered into an At-The-Market (ATM) equity offering agreement with Titan Partners Securities LLC to sell up to $25 million of common stock.
🚩 Red Flags
- Potential for significant shareholder dilution via the ATM offering.
- ATM offerings are often used by micro-cap companies to bolster immediate liquidity, which can signal cash runway concerns.
📋 Key Facts
- Entered into a Sales Agreement on August 14, 2026.
- Aggregate maximum offering amount: $25,000,000.
- Sales agent: Titan Partners Securities LLC.
- Commission rate: Up to 3% of the gross sales price per share.
- The offering will be conducted via an existing shelf Registration Statement on Form S-3 (Reg. No. 333-293307).
- Sales can occur through ordinary brokers' transactions on Nasdaq at market prices.
HeartBeam, Inc. filed an amendment to its 8-K to disclose the finalized separation and advisory agreements for Robert P. Eno. The agreement includes a $300,000 cash severance payment and full acceleration of his equity awards.
🚩 Red Flags
- Significant cash outflow ($300k) for executive severance in a micro-cap context.
- Full acceleration of all outstanding equity awards can lead to significant dilution and potential downward pressure on stock price upon exercise/sale.
📋 Key Facts
- Robert P. Eno entered into a Separation Agreement and Release on July 30, 2026.
- The separation includes a lump sum cash payment of $300,000 (equivalent to 9 months of base salary).
- All outstanding stock options and RSUs held by Mr. Eno will undergo full acceleration in vesting.
- Post-termination exercise period for stock options is extended until December 31, 2027, or the option's maximum term.
- Mr. Eno will serve as a non-employee advisor under an Advisory Agreement with a $1,000 one-time retainer fee.
HeartBeam, Inc. held its annual meeting of stockholders on July 31, 2026, reporting the election of seven directors and the ratification of CBIZ CPAs P.C. as independent auditors. Notably, a proposal to increase authorized shares under the 2022 Equity Incentive Plan was rejected by shareholders.
🚩 Red Flags
- Shareholders rejected a proposal to increase authorized shares for the Equity Incentive Plan, which may indicate investor skepticism regarding dilution or management's compensation structure.
📋 Key Facts
- Annual meeting held virtually on July 31, 2026.
- Quorum reached with 52.34% of outstanding votes represented (29,050,272 votes).
- Seven directors were elected to one-year terms: Richard Ferrari, Branislav Vajdic, PhD, George A. de Urioste, Marga Ortigas-Wedekind, Willem Elfrink, Kenneth Nelson, and Michael Jaff.
- Shareholders ratified the appointment of CBIZ CPAs P.C. as independent auditors for fiscal year 2026.
- Proposal to increase authorized shares in the 2022 Equity Incentive Plan by 3,000,000 was NOT approved.
HeartBeam, Inc. received a deficiency notice from Nasdaq on June 30, 2026, due to the company's stock price falling below the $1.00 minimum bid price requirement for 30 consecutive business days.
🚩 Red Flags
- Delisting notice from Nasdaq
- Stock price has been below $1.00 for at least 30 consecutive business days
- Risk of delisting if compliance is not achieved by December 28, 2026
📋 Key Facts
- Received deficiency notice from Nasdaq Listing Qualifications Department on June 30, 2026.
- The violation is based on a failure to maintain a minimum bid price of $1.00 per share (Nasdaq Listing Rule 5550(a)(2)).
- The company has a 180-day compliance period ending December 28, 2026, to regain compliance.
- To regain compliance, the stock must close at or above $1.00 for at least ten consecutive business days before the deadline.
- A second 180-day extension may be available if certain market value requirements are met.
HeartBeam, Inc. announced the departure of CEO Robert P. Eno and Board member Mark Strome, effective June 30, 2026, as part of a strategic reorganization. Dr. Branislav Vajdic will assume the role of principal executive officer until a new CEO is appointed.
🚩 Red Flags
- Simultaneous departure of the CEO and a Board member during a 'strategic reorganization'.
- Leadership vacuum: The company is operating without a permanent CEO, relying on interim leadership from the Founder and Executive Chairman.
- Potential for instability following the sudden resignation of a Board member.
📋 Key Facts
- CEO Robert P. Eno to depart his roles as CEO and Board member effective June 30, 2026.
- Departure described as a mutual agreement related to strategic reorganization; no dispute or disagreement reported.
- Eno is expected to enter into a consulting agreement in an advisory capacity following his departure.
- Mark Strome resigned from the Board and all committees effective immediately (June 18, 2026).
- Dr. Branislav Vajdic (Founder/President) will serve as principal executive officer effective July 1, 2026.
HeartBeam, Inc. announced new compensatory arrangements for its President and Founder, Dr. Branislav Vajdic, including a performance-based restricted stock unit (PRSU) award of 2.8 million units and a transaction bonus tied to a potential Change in Control.
🚩 Red Flags
- Significant equity issuance (2.8M units) to the Founder/President may lead to further dilution for existing shareholders.
- The Transaction Bonus is explicitly tied to 'Change in Control' events, suggesting management incentives are heavily aligned with a sale of the company rather than long-term organic growth.
📋 Key Facts
- On June 15, 2026, the Board approved a PRSU award for Dr. Branislav Vajdic covering 2,800,000 restricted stock units.
- PRSU vesting is contingent upon specific operational, software, product-development, and clinical study milestones.
- Service-based vesting occurs in thirds over three years, subject to continued service.
- A Transaction Bonus Agreement was approved, which triggers payments only if specified market capitalization and per-share price thresholds are met during a Qualifying Change in Control.
HeartBeam, Inc. closed a $10.0 million underwritten public offering of 12.5 million shares of common stock at a price of $0.80 per share. The company intends to use the proceeds to commercialize its FDA-cleared 12-lead synthesized ECG system and advance its AI and heart attack detection initiatives.
🚩 Red Flags
- Significant dilution from the issuance of 12.5 million new shares.
- Issuance of underwriter warrants (5% coverage) creates additional future dilution potential.
- Relatively short lock-up period of 75 days for insiders.
📋 Key Facts
- Offering of 12,500,000 shares of common stock at $0.80 per share.
- Gross proceeds of approximately $10.0 million before expenses.
- Underwriter (Titan Partners Group LLC) granted a 30-day option to purchase up to 1,875,000 additional shares.
- Underwriter received warrants to purchase 5% of the total shares sold, exercisable for five years.
- Company, officers, and directors are subject to a 75-day lock-up period.
- Closing of the offering occurred on April 16, 2026.
HeartBeam, Inc. received a 'Not Substantially Equivalent' (NSE) letter from the FDA regarding its 510(k) application for its 12-Lead ECG Synthesis Software. This represents a significant regulatory setback for a core product line.
🚩 Red Flags
- Regulatory rejection: The NSE letter indicates the FDA does not believe the device is substantially equivalent to a predicate device, blocking market entry for this specific software.
- Product pipeline risk: Failure of a key regulatory application can significantly impact revenue projections and burn rate.
📋 Key Facts
- FDA issued an NSE letter on November 20, 2025, for the 12-Lead Electrocardiogram (ECG) Synthesis Software application.
- The company is attempting to resolve the issue with the FDA using existing clinical data.
- The company is pivoting focus toward its novel 3D ECG system, which received FDA 510(k) clearance in December 2024.
HeartBeam, Inc. held its annual meeting of stockholders on July 11, 2025, reporting results for director elections and shareholder proposals.
🚩 Red Flags
- Significant broker non-votes (11,579,760) across all voting items suggests a high level of unrepresented or non-voting equity in the denominator.
📋 Key Facts
- Annual Meeting held virtually via live webcast on July 11, 2025.
- Quorum was established with 18,702,366 votes (approx. 55.32% of outstanding votes).
- Nine nominees for director were elected to one-year terms.
- Shareholders ratified the appointment of CBIZ CPAs P.C. as independent auditors for fiscal year ending Dec 31, 2025.
- Proposal to amend the 2022 Equity Incentive Plan to increase authorized shares from 8.9M to 11.9M was approved.
HeartBeam, Inc. announced the appointment of its current CEO, Robert Eno, to the Company's Board of Directors, effective May 5, 2025. This move expands the Board from eight to nine members.
📋 Key Facts
- Robert Eno (current CEO) appointed as a member of the Board of Directors.
- Effective date of appointment: May 5, 2025.
- Board size expanded from eight to nine members to accommodate the new director.
- No family relationships exist between Mr. Eno and current officers or directors.
- No related party transactions were reported in connection with this appointment.
HeartBeam, Inc. has announced the resignation of its independent auditor, Marcum LLP, and the appointment of CBIZ CPAs P.C. as its new independent registered public accounting firm effective immediately.
🚩 Red Flags
- Auditor change combined with existing 'going concern' language (substantial doubt about ability to continue).
- Disclosed material weaknesses in internal control over financial reporting.
- Lack of proper approval processes, documentation, and insufficient GAAP experience noted as deficiencies.
📋 Key Facts
- Marcum LLP resigned as the Company's independent auditor on April 21, 2025.
- CBIZ CPAs P.C. has been engaged to serve as the independent auditor for the fiscal year ending December 31, 2025.
- The prior auditor (Marcum) issued an explanatory paragraph in the FY2024 report regarding substantial doubt about the Company's ability to continue as a going concern.
- The Company disclosed material weaknesses in internal control over financial reporting for the two most recent fiscal years, including lack of formal risk assessment and insufficient staff for segregation of duties.
HeartBeam, Inc. announced the full exercise and closing of an over-allotment option related to its recent public offering. The transaction generated approximately $1.5 million in gross proceeds from the sale of 864,033 shares.
📋 Key Facts
- The company completed a primary public offering on February 14, 2025, for 5,882,353 shares at $1.70 per share ($10M gross proceeds).
- Underwriters exercised the bulk of the Over-allotment Option (864,033 shares) on February 21, 2025.
- The closing of the over-allotment purchase occurred on February 25, 2025.
- Over-allotment transaction generated approximately $1.5 million in gross proceeds before expenses.
HeartBeam, Inc. completed a firm commitment underwritten offering of 5,882,353 shares at $1.70 per share, raising approximately $10 million in gross proceeds. The offering included the issuance of warrants to the underwriter representing 10% of the shares issued.
🚩 Red Flags
- Significant dilution: Issuance of over 5.8 million new shares at a low price point ($1.70).
- Warrant overhang: Underwriter received warrants equal to 10% of the offering, which may lead to further dilution upon exercise.
📋 Key Facts
- Offering size: 5,882,353 shares of common stock.
- Public offering price: $1.70 per share.
- Gross proceeds: Approximately $10 million (before expenses).
- Underwriter: Public Ventures, LLC dba MDB Capital.
- Closing Date: February 14, 2025.
- Underwriter Warrants: 588,235 shares at an exercise price of $2.125 (125% of offering price), exercisable starting Feb 9, 2026.
- Lock-up period: 180 days for directors and executive officers.
HeartBeam, Inc. announced a leadership transition where founder and current CEO Branislav Vajdic will move to the role of President, effective October 21, 2024. Robert Eno, previously President, has been appointed as the new Chief Executive Officer.
🚩 Red Flags
- Management turnover in a micro-cap company can sometimes signal internal strategic shifts or friction, though this is framed as a planned transition.
📋 Key Facts
- Robert Eno appointed CEO effective October 21, 2024; annual base salary of $400,000 plus a potential 60% incentive bonus.
- Branislav Vajdic (Founder/current CEO) transitioning to President role effective October 21, 2024; no changes to current compensation structure.
- The transition is described as 'long-planned' and intended to allow the founder to focus on R&D and AI applications.
- Robert Eno brings significant experience from HeartFlow (FFRCT) and Preview Medical.
HeartBeam, Inc. announced the appointment of Timothy Cruickshank as Chief Financial Officer, effective September 9, 2024. The new CFO brings experience from ImpediMed, where he helped transition the company to a SaaS-based business model.
📋 Key Facts
- Timothy Cruickshank appointed as CFO effective September 9, 2024.
- Annual base salary of $385,000 paid semi-monthly.
- Eligible for an incentive bonus of up to 45% of annual base salary based on corporate goals.
- Potential grant of options to purchase 400,000 shares of Common Stock subject to Board approval.
- Cruickshank previously served as CFO at ImpediMed from October 2019 through March 2024.
HeartBeam, Inc. held its annual meeting of stockholders on June 12, 2024. The company successfully elected eight directors and ratified the appointment of Marcum LLP as its independent auditor.
📋 Key Facts
- Annual Meeting held virtually via live webcast on June 12, 2024.
- Quorum was established with 15,510,613 votes (approx. 58.91% of outstanding votes) represented.
- Eight directors were elected to one-year terms: Richard Ferrari, Branislav Vajdic, PhD, George A. de Urioste, Marga Ortigas-Wedekind, Willem Elfrink, Mark Strome, Kenneth Nelson, and Michael Jaff.
- Ratification of Marcum LLP as independent registered public accounting firm for FY2024 was approved.
- Proposal to amend the 2022 Equity Incentive Plan to increase authorized shares from 5.9M to 8.9M was approved.
HeartBeam, Inc. entered into an 'at the market' (ATM) sales agreement with Public Ventures, LLC to potentially sell up to $17 million in common stock. This follows the termination of a previous sales agreement with A.G.P./Alliance Global Partners.
🚩 Red Flags
- Potential significant dilution of existing shareholders through the $17M ATM offering.
- The company is seeking capital for 'working capital and other general corporate purposes,' which often indicates a need to sustain operations (burn rate management).
📋 Key Facts
- Entered into PV Sales Agreement with Public Ventures, LLC on May 2, 2024.
- The offering allows for the sale of up to approximately $17,000,000 in common stock.
- Sales will be conducted via an 'at the market' (ATM) method under a previously filed S-3 registration statement.
- Public Ventures will receive a 3.0% commission on aggregate gross proceeds.
- Company intends to use net proceeds for working capital and general corporate purposes.
- Terminated previous Sales Agreement with A.G.P./Alliance Global Partners on May 1, 2024.
HeartBeam, Inc. announced the retirement of its Chief Financial Officer, Richard Brounstein, effective February 1, 2024. The departure is characterized as a planned retirement without disagreement with management or the Board.
🚩 Red Flags
- None identified; retirement is characterized as planned and amicable.
📋 Key Facts
- Richard Brounstein retired as CFO effective February 1, 2024.
- Mr. Brounstein has been with the company since 2015.
- The departure is not due to any disagreement regarding operations, policies, or practices.
- Mr. Brounstein will remain as a consultant to assist with the transition of duties.